Cell and Gene Therapy Catapult, a regenerative medicine company, agreed to acquire the vaccine manufacturing business and assets of Benchmark Holdings, the aquaculture genetics, health and advanced nutrition company, for $20m. The transaction is a significant milestone in Benchmark's strategy to reduce its cost base and focus on its core areas to achieve profitability. The proceeds from the sale do not represent a profit to Benchmark, but are based on the facility's asset value and have been agreed to support the Government's vaccine strategy.